MAPT and Alzheimer disease: The admixture of AD patients (who are characterized by an increase in CSF p-tau), primarily in the bvFTD cohorts and secondarily in the CBS and nfa-PPA cohorts, could hypothetically cover a possible inherent decrease in p-tau in these disorders.